Trevi Therapeutics, Inc. (TRVI) › Operating Cash FlowTrevi Therapeutics, Inc. (TRVI) — Operating Cash FlowAnnual figures by period end, from SEC filings.2018-12-31: -$18.29M2019-12-31: -$23.09M2020-12-31: -$29.00M2021-12-31: -$28.95M2022-12-31: -$28.18M2023-12-31: -$31.71M2024-12-31: -$38.26M2025-12-31: -$42.09M-$42.09M2018-12-31Operating Cash Flow (USD)2025-12-31Period endedOperating Cash FlowChange YoYSource filing2025-12-31-$42.09M—2026-03-17From 2025-01-012024-12-31-$38.26M—2026-03-17From 2024-01-012023-12-31-$31.71M—2025-03-18From 2023-01-012022-12-31-$28.18M—2024-03-20From 2022-01-012021-12-31-$28.95M—2023-03-16From 2021-01-012020-12-31-$29.00M—2022-03-17From 2020-01-012019-12-31-$23.09M—2021-03-25From 2019-01-012018-12-31-$18.29M—2020-03-16From 2018-01-01Other metrics: RevenueCost of RevenueGross ProfitOperating IncomeNet IncomeEPS (Diluted)Total AssetsTotal LiabilitiesShareholders' EquityCash & EquivalentsCapital ExpendituresShares OutstandingDividends Per ShareWeighted Average Diluted SharesEPS (Basic)